LGALS3 and cancer: This, together with the observation of their lack of cytotoxicity and genotoxicity, suggests that these non-carbohydrate small molecule galectin-3 inhibitors represent a novel class of galectin-3 inhibitors and can offer significant potential to be developed as galectin-3-targeted novel therapeutic drugs for cancer treatment.